Nova Reuma Domyslawska I Rusilowicz Lekarza Reumatologa I Fizjoterapeuty sp.p. — Clinical Trial Site

21 Registered trials

5 Currently recruiting

Organisation

Nova Reuma Domyslawska I Rusilowicz Lekarza Reumatologa I Fizjoterapeuty sp.p.

Location

Bialystok, Poland

Identifier

ORG-100044247

Address

Ul Prowiantowa 15/4, 15-707, Poland

Departments

40824: Nova Reuma Domysławska i Rusiłowicz Społka Partnerska Lekarza Reumatologa i Fizjoterapeuty
Centrum Reumatologii i Rehabilitacji NOVA REUMANOVA REUMA
N/A
NA
Not applicable
Nova Reuma
Nova Reuma Domysławska i Rusiłowicz – Partnership of Rheumatologist and Physiotherapist
Nova Reuma Domysławska I Rusiłowicz Spółka Partnerska Lekarza Reumatologa I Fizjoterapeuty
Nova Reuma Społka Partnerska

Clinical trials at this site (21)

Search interface

A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate r… Pending

2025-524005-32-00 Rheumatoid arthritis 4
C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN … Recruiting

2022-502739-20-00 Active Idiopathic Inflammatory Myopathies (Including De 5 2023-11-16
A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting

2024-513111-27-00 Psoriatic Arthritis 5 2025-06-26
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici… Recruiting

2024-516219-25-00 psoriatic arthritis 5 2025-03-25
An open-label extension study with dazukibart for participants with idiopathic inflammatory myopathies (including DM or PM) who have complet… Recruiting

2024-514648-10-00 Idiopathic Inflammatory Myopathy (including dermatomyos 5 2025-03-14
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1) Recruiting

2022-500699-76-00 Active Systemic Lupus Erythematosus (SLE) 5 2023-05-18
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended

2024-516609-22-00 Primary Sjögren’s Disease 5 2025-04-15
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
A study to learn how well bimekizumab works and how safe it is in adults with psoriatic arthritis Ended

2024-511738-11-00 Psoriatic arthritis 5 2024-12-18
Phase 2 Placebo-controlled Study to Assess the Safety, Efficacy, and PK of ESK-001 in SLE Ended

2022-502105-15-00 Systemic lupus erythematosus 4 2023-10-20
A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus (EMERALD) Ended

2023-505635-13-00 Systemic lupus erythematosus 5 2022-06-10
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-2) Ended

2022-502841-91-00 Crohn’s Disease 5 2020-08-12
A study to evaluate safety and efficacy of Empasiprubart in adults with Dermatomyositis Ended

2023-508337-14-00 Myositis, Dermatomyositis 4 2025-03-18
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to… Ended

2023-504564-42-00 Moderate to Severe Rheumatoid Arthritis 4 2024-04-08
A clinical study of MK-6194 for the treatment of Systemic Lupus Erythematosus (SLE) (MK-6194-006) Ended

2023-505520-61-00 Systemic Lupus Erythematosus 10 2024-03-11
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis Ended

2023-505127-31-00 Rheumatoid Arthritis 3 2024-02-08
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis Ended

2022-502994-40-00 Rheumatoid Arthritis 4 2023-09-04
A study evaluating the effects of GLPG3667 given as oral treatment for up to 24 weeks in adults with dermatomyositis Ended

2022-501097-19-00 dermatomyositis 4 2023-08-09
A Study of Peresolimab (LY3462817) in Adults Participants With Moderately-to-Severely Active Rheumatoid Arthritis Ended

2022-501425-20-00 Rheumatoid Arthritis Arthritis Joint Diseases Muscul 4 2023-04-03
The WILLOW study with enpatoran in SLE and CLE (SCLE and/or DLE) Ended

2024-510872-18-00 Systemic lupus erythematosus (SLE) and cutaneous lupus 4 2022-05-09